You are here: Industry Insights > NICE

News List

NICE stands firm on 'no' vote for Roche's Perjeta in postsurgery breast cancer fiercepharma
August 21, 2018
Back in June, England’s cost watchdog refused to recommend Roche’s Perjeta for postsurgery breast cancer patients. And it’s sticking by that decision.
NICE does not recommend NHS use of Biogen’s nusinersen for SMA pharmaceutical-technology
August 17, 2018
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Biogen’s Spinraza (nusinersen) for routine use by the National Health Service (NHS) to treat spinal muscular atrophy (SMA).
Draft guidelines reject NHS funding for Biogen’s Spinraza pharmatimes
August 15, 2018
The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.
NICE suspends review of Vertex’s Symkevi for cystic fibrosis pharmaceutical-technology
August 14, 2018
The UK’s National Institute for Health and Care Excellence (NICE) has suspended its review of Vertex Pharmaceuticals’ cystic fibrosis (CF) drug Symkevi (tezacaftor/ivacaftor) after the company failed to submit evidence to NICE regarding the clinical and c
NICE recommends Pfizer's Besponsa in rare leukaemia following review pharmafile
August 10, 2018
Pfizer has revealed that NICE has finally decided to recommend its CD22-targeting monoclonal antibody Besponsa (inotuzumab ozogamicin) in the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adult patient
NICE recommends Eli Lilly's psoriatic arthritis drug pharmafile
August 10, 2018
Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option in England and Wales for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying anti
NICE changes its mind on Pfizer’s Besponsa pharmatimes
August 10, 2018
NICE has reversed its draft decision rejecting Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia, meaning the drug will now be available on the NHS in England and Wales.
NICE backing for Keytruda in classical Hodgkin lymphoma pharmatimes
July 27, 2018
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
MPs call on government to help with Orkambi debate pharmatimes
July 23, 2018
MPs are calling on NHS England and Vertex to come to an agreement over the price of cystic fibrosis drug Orkambi.
NICE backs radionuclide therapy for some neuroendocrine tumours pharmatimes
July 23, 2018
A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page